Loperamide

Pharmacologic Category

Antidiarrheal

Dosing: Adult

Acute diarrhea: Oral: Initial: 4 mg, followed by 2 mg after each loose stool (maximum: 16 mg/day)

Chronic diarrhea: Oral: Initial: 4 mg, followed by 2 mg after each loose stool (maximum: 16 mg/day); maintenance dose should be slowly titrated downward to minimum required to control symptoms (usual: 4 to 8 mg/day as a single dose or in divided doses; maximum: 16 mg/day). If clinical improvement is not observed after at least 10 days of treatment with 16 mg/day, symptoms are unlikely to be controlled by further administration; treatment may be continued if diarrhea cannot be adequately controlled with diet or other therapy.

Traveler's diarrhea: Oral: Initial: 4 mg after first loose stool, followed by 2 mg after each subsequent stool (maximum dose: 16 mg/day [OTC: 8 mg/day]); (duration of therapy: ≤48 hours); in patients with moderate-to-severe illness receiving an antibiotic, loperamide is recommended as adjunctive therapy to decrease duration of diarrhea (ACG [Riddle 2016]; however, acquisition of extended-spectrum-beta-lactamase-producing pathogens may be more common when loperamide and antibiotics are coadministered (CDC 2018). Do not use loperamide in cases of dysentery (IDSA [Hill 2006]).

Cancer treatment-induced diarrhea (off-label use): Oral: 4 mg, followed by 2 mg every 2 to 4 hours or after each loose stool (more persistent diarrhea will require the higher frequency); doses >16 mg/day may not provide benefit (Andreyev 2014) or 4 mg, followed by 2 mg every 4 hours or after each loose stool; Maximum: 16 mg/day (Benson 2004; Morturano 2012) or 4 mg followed by 2 mg every 2 hours (may utilize 4 mg every 4 hours at night) until 12 hours have passed without a loose bowel movement (Sharma 2005).

Neratinib-induced diarrhea, prophylaxis (off-label use): Oral: 4 mg 3 times daily (days 1 to 14 of neratinib therapy), followed by 4 mg twice daily (days 15 to 56 of neratinib therapy), followed by 4 mg as needed up to a maximum of 16 mg/day (days 57 to 365 of neratinib therapy) (Nerlynx product labeling 2018). Note: Antidiarrheal prophylaxis is recommended during the first 2 cycles of neratinib therapy; initiate with the first neratinib dose. Titrate to 1 to 2 bowel movements/day. Additional antidiarrheal medication may be required for loperamide-refractory diarrhea.

Irinotecan-induced delayed diarrhea (off-label use): Oral: 4 mg after first loose or frequent bowel movement, then 2 mg every 2 hours (4 mg every 4 hours at night) until 12 hours have passed without a bowel movement (Rothenberg 1996).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing; use with caution.

Dosing: Renal Impairment: Adult

No dosage adjustment necessary.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; use with caution.

Dosing: Pediatric

Acute diarrhea: Note: Loperamide is not recommended for management of infectious diarrhea in pediatric patients (IDSA [Shane 2017]). For patients who are small for chronological age, consider dosing according to weight range and not by age group. Use lowest effective dose for shortest duration.

Children 2 to <12 years: Oral:

2 to 5 years weighing 13 to <21 kg: Initial: 1 mg with first loose stool followed by 1 mg/dose after each subsequent loose stool; maximum daily dose: 3 mg/day

6 to 8 years weighing 21 to 27 kg: Initial: 2 mg with first loose stool followed by 1 mg/dose after each subsequent loose stool; maximum daily dose: 4 mg/day

9 to 11 years weighing 27.1 to 43 kg: Initial: 2 mg with first loose stool followed by 1 mg/dose after each subsequent loose stool; maximum daily dose: 6 mg/day

Children ≥12 years and Adolescents: Oral: Initial: 4 mg with first loose stool followed by 2 mg/dose after each subsequent loose stool; maximum daily dose: 8 mg/day

Chronic diarrhea; secondary to intestinal failure, short-bowel syndrome, or other noninfectious causes: Limited data available; dosing regimens variable: Infants ≥2 months and Children: Oral: 0.08 to 0.24 mg/kg/day divided 2 to 3 times/day was reported in a case series of 10 pediatric patients (age range: 2 to 52 months) (Buts 1975). In a case series of six infants and young children, higher dosing was described: Initial: 1 to 1.5 mg/kg/day in 4 divided doses with subsequent dose decreased as stool output and diet tolerance improved and patient weight increased. Reported final dose range of 0.25 to 0.5 mg/kg/day in 2 divided doses was used long-term until patient achieved target weight and dietary goals; reported duration of therapy: 6 months to ~2 years (Sandhu 1983); maximum single dose: 2 mg

Irinotecan-induced (delayed) diarrhea: Limited data available; consult individual protocols; some organizations have used the following:

Fixed dosing (Children's Oncology Group 2009):

Children ≥2 to 12 years:

<13 kg: Initial: 0.5 mg after the first loose bowel movement, followed by 0.5 mg every 3 hours while awake; during the night, may administer every 4 hours; maximum daily dose: 4 mg/day

13 kg to <20 kg: Initial: 1 mg after the first loose bowel movement, followed by 1 mg every 4 hours; maximum daily dose: 6 mg/day

20 kg to <30 kg: Initial: 2 mg after the first loose bowel movement, followed by 1 mg every 3 hours while awake; during the night, may administer every 4 hours; maximum daily dose: 8 mg/day

30 kg to <43 kg: Initial: 2 mg after the first loose bowel movement, followed by 1 mg every 2 hours while awake; during the night, may administer every 4 hours; maximum daily dose: 12 mg/day

Adolescents weighing ≥43 kg: Initial: 4 mg after the first loose bowel movement, followed by 2 mg after each loose stool; maximum daily dose: 16 mg/day

Weight-directed dosing (Vassal 2007): Children and Adolescents 2 to <15 years:

Grade 1 or 2: 0.03 mg/kg/dose every 4 hours

Grade 3 or 4: 0.06 mg/kg/dose every 4 hours

Maximum single dose dependent upon weight:

<13 kg: 0.5 mg

13 to <20 kg: 1 mg

20 to <43 kg: Initial: 2 mg; subsequent doses: 1 mg

≥43 kg: Initial: 4 mg; subsequent doses: 2 mg

Dosing: Renal Impairment: Pediatric

No adjustment required.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer labeling. Due to possible effects on first-pass metabolism, use with caution and monitor closely for signs of CNS toxicity.

Use: Labeled Indications

Diarrhea:

Rx labeling: Control and symptomatic relief of chronic diarrhea associated with inflammatory bowel disease in adults; acute nonspecific diarrhea in patients ≥2 years; to reduce volume of ileostomy discharge

OTC labeling: Control of symptoms of diarrhea, including Traveler's diarrhea

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

Cancer treatment-induced diarrheaLevel of Evidence [B, G]

Data from clinical trials, clinical practice guidelines, and reviews support the use of loperamide in the management of cancer treatment-induced diarrhea, including irinotecan-induced diarrhea ^Ref.

Traveler’s diarrheaLevel of Evidence [G]

The American College of Gastroenterology recommends adjunctive loperamide therapy in patients receiving antibiotics for Traveler’s diarrhea to decrease duration of diarrhea and increase chance for a cure ^Ref.

Level of Evidence Definitions

Level of Evidence Scale

Clinical Practice Guidelines

Irritable Bowel Syndrome:

American Gastroenterological Association (AGA), “American Gastroenterological Association Institute Guideline on the Pharmacological Management of Irritable Bowel Syndrome,” 2014

Traveler’s Diarrhea:

American College of Gastroenterology (ACG), “ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults,” May 2016

CDC, “The Yellowbook: Travelers’ Diarrhea,” 2018

IDSA, "The Practice of Travel Medicine”, 2006

Oncology: Palliative Care:

National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology™, Palliative Care

Administration: Oral

Administer with plenty of clear fluids to prevent dehydration.

Oral solution: Shake well before administering dose.

Cancer treatment-induced diarrhea: Consider administering 30 minutes prior to eating 4 times daily to slow gastrocolic reflex (Andreyev 2014).

Administration: Pediatric

Oral: Drink plenty of fluids to help prevent dehydration.

Oral solution: Shake well before administering dose.

Dietary Considerations

Some products may contain sodium.

Storage/Stability

Store between 20°C and 25°C (68°F and 77°F).

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to treat diarrhea.

• It is used to lower ostomy output.

Frequently reported side effects of this drug

• Fatigue

• Loss of strength and energy

Other side effects of this drug: Talk with your doctor right away if you have any of these signs of:

• Severe dizziness

• Passing out

• Chest pain

• Fast heartbeat

• Abnormal heartbeat

• Severe nausea

• Severe vomiting

• Abdominal pain

• Constipation

• Abdominal edema

• Bloating

• Black, tarry, or bloody stools

• Unable to pass urine

• Change in amount of urine passed

• Signs of a significant reaction like wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this medicine. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not specific medical advice and does not replace information you receive from the healthcare provider. You must talk with the healthcare provider for complete information about the risks and benefits of using this medicine.

Medication Safety Issues

Sound-alike/look-alike issues:

International issues:

Contraindications

Hypersensitivity to loperamide or any component of the formulation; abdominal pain without diarrhea; children <2 years; acute dysentery; acute ulcerative colitis; bacterial enterocolitis (caused by Salmonella, Shigella, and Campylobacter); pseudomembranous colitis associated with broad-spectrum antibiotic use.

Canadian labeling: Additional contraindications (not in the US labeling): When constipation should be avoided; when the inhibition of peristalsis should be avoided

OTC labeling: When used for self-medication, do not use if stool is bloody or black.

Documentation of allergenic cross-reactivity for antidiarrheals is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.

Warnings/Precautions

Concerns related to adverse effects:

• Allergic reactions: Rare cases of anaphylaxis and anaphylactic shock have been reported.

• CNS effects: May cause drowsiness or dizziness, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).

• GI effects: Discontinue promptly if constipation, abdominal pain, abdominal distension, blood in stool, or ileus develop. Do not use when peristalsis inhibition should be avoided due to potential for ileus, megacolon and/or toxic megacolon.

• Torsades de pointes and sudden death: [US Boxed Warning]: Cases of torsades de pointes, cardiac arrest, and death have been reported with the use of a higher than recommended dosage. Contraindicated in pediatric patients <2 years. Avoid dosages higher than recommended in patients ≥2 years due to the risk of serious cardiac adverse reactions. Cases of syncope and ventricular tachycardia have been reported in adults receiving the recommended dose of loperamide. Cases of cardiac arrest, syncope, and respiratory depression have been reported in pediatric patients <2 years. Avoid use in patients with risk factors for QT prolongation (eg, congenital long QT syndrome, history of cardiac arrhythmias or other cardiac conditions, elderly, electrolyte abnormalities) and in combination with others drugs known to prolong the QT interval.

Disease-related concerns:

• AIDS patients: Stop therapy at the first sign of abdominal distention; cases of toxic megacolon have occurred in AIDS patients with infectious colitis (due to viral or bacterial pathogens).

• Hepatic impairment: Use with caution in patients with hepatic impairment due to reduced first-pass metabolism; monitor for signs of CNS toxicity.

Concurrent drug therapy issues:

• Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.

Special populations:

• Elderly: Use with caution in the elderly; may be more susceptible to drug-associated effects on the QT interval.

• Pediatric: Use with caution in young children as response may be variable because of dehydration. Contraindicated in children <2 years.

Dosage form specific issues:

• Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.

Other warnings/precautions:

• Appropriate use: Loperamide is a symptom-directed treatment; if an underlying diagnosis is made, other disease-specific treatment may be indicated. Concurrent fluid and electrolyte replacement is often necessary in all age groups depending upon severity of diarrhea.

• Duration of use: If diarrhea lasts longer than 2 days, symptoms worsen, or abdominal swelling or bulging develops, discontinue use and consult healthcare provider.

• Self medication (OTC use): Consult health care provider prior to using, if taking antibiotics, if pregnant or breastfeeding, or in the presence of fever, mucus in stool, or a history of liver disease. Serious heart problems may occur if taken more than directed.

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

Elderly are particularly sensitive to fluid and electrolyte loss. This generally results in lethargy, weakness, and confusion. Repletion and maintenance of electrolytes and water are essential in the treatment of diarrhea. Drug therapy must be limited in order to avoid toxicity with this agent.

Warnings: Additional Pediatric Considerations

When managing acute dysentery, concurrent fluid and electrolyte replacement is often necessary in all age groups depending upon severity of diarrhea; young pediatric patients are particularly susceptible to dehydration and electrolyte imbalances. Antidiarrheal agents are not recommended as part of the management of acute gastroenteritis in infants and children because they do not address the underlying cause (ie, do not treat the infection) and have a risk of serious adverse events (CDC 2003). A metaanalysis evaluating the use of loperamide for adjunct treatment of acute bacterial gastroenteritis in pediatric patients identified that infants and children <3 years, malnourished, moderately to severely dehydrated, or those with bloody diarrhea have a higher risk of serious adverse events (ileus, lethargy, death) even at therapeutic doses (≤0.25 mg/kg/day of loperamide); the potential benefit of loperamide therapy does not outweigh risks; use should be avoided in pediatric patients (IDSA [Shane 2017]; Li 2007). Although data suggests that older children with milder infection and adolescents may see benefit from loperamide therapy, including decreased duration of diarrhea and stool counts, use is not recommended (IDSA [Shane 2017]); if used, patients should be monitored closely for adverse effects or worsening of infection (CDC 2003; Li 2007).

Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, >3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).

Pregnancy Risk Factor

C

Pregnancy Considerations

Adverse effects have not been observed in animal reproduction studies. Information related to loperamide use in pregnancy is limited and data is conflicting (Einarson 2000; Källén 2008). For acute diarrhea in pregnant women, some clinicians recommend oral rehydration and dietary changes; loperamide in small amounts may be used only if symptoms are disabling (Wald 2003).

Breast-Feeding Considerations

Loperamide may be present in breast milk.

Studies evaluating milk concentrations of loperamide following maternal use have not been located. Available information is based on studies using loperamide oxide, the prodrug of loperamide, conducted in six women given 2 doses of oral loperamide oxide 12 hours apart, within 47 hours of delivery. Loperamide concentrations in breast milk ranged from not detectable (<0.1 ng/mL) to 0.61 ng/mL, compared to maternal plasma concentrations of 0.2 ng/mL to 1.71 ng/mL (Nikodem 1992). Therapeutic use of loperamide is contraindicated in children <2 years of age. Breastfeeding is not recommended by the manufacturer.

Briggs' Drugs in Pregnancy & Lactation

• Loperamide

Adverse Reactions

1% to 10%:

Central nervous system: Dizziness (1%)

Gastrointestinal: Constipation (2% to 5%), abdominal cramps (≤3%), nausea (≤3%)

<1%, postmarketing, and/or case reports: Abdominal discomfort, abdominal distention, abdominal pain, anaphylactic shock, anaphylactoid reaction, angioedema, bullous rash (rare), drowsiness, dyspepsia, erythema multiforme (rare), fatigue, flatulence, hypersensitivity reaction, megacolon, paralytic ileus, pruritus, skin rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), toxic megacolon, urinary retention, urticaria, vomiting, xerostomia

* See Cautions in AHFS Essentials for additional information.

Toxicology

• Opioids

Metabolism/Transport Effects

Substrate of CYP2B6 (minor), CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1; Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions Open Interactions

Desmopressin: Loperamide-Loperamide Oxide may increase the serum concentration of Desmopressin. Risk C: Monitor therapy

Eluxadoline: Loperamide-Loperamide Oxide may enhance the constipating effect of Eluxadoline. Risk C: Monitor therapy

Erdafitinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Risk C: Monitor therapy

Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. Risk C: Monitor therapy

Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Risk X: Avoid combination

Lumacaftor and Ivacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor and Ivacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Risk C: Monitor therapy

P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). Risk C: Monitor therapy

QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk). Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk. Risk C: Monitor therapy

QuiNIDine: May enhance the CNS depressant effect of Loperamide-Loperamide Oxide. Loperamide-Loperamide Oxide may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Loperamide-Loperamide Oxide. Risk C: Monitor therapy

Ramosetron: Loperamide-Loperamide Oxide may enhance the constipating effect of Ramosetron. Risk C: Monitor therapy

Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. Risk C: Monitor therapy

Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide. Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction. Risk D: Consider therapy modification

Monitoring Parameters

Signs of CNS toxicity in patients with hepatic impairment.

Advanced Practitioners Physical Assessment/Monitoring

Assess for cause of diarrhea before administering first dose. Assess patient with liver impairment for signs of CNS toxicity.

Nursing Physical Assessment/Monitoring

Educate patients to not take higher than recommended doses due to risk of torsades de pointes or sudden death. Educate patients to report persistent diarrhea.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Capsule, Oral, as hydrochloride:

Imodium A-D: 2 mg [contains brilliant blue fcf (fd&c blue #1), peg-40 hydrogenated castor oil]

Generic: 2 mg

Liquid, Oral, as hydrochloride:

Imodium A-D: 1 mg/7.5 mL (120 mL, 240 mL) [contains brilliant blue fcf (fd&c blue #1), fd&c yellow #10 (quinoline yellow), propylene glycol, sodium benzoate]

Imodium A-D: 1 mg/7.5 mL (120 mL, 240 mL) [contains brilliant blue fcf (fd&c blue #1), fd&c yellow #10 (quinoline yellow), propylene glycol, sodium benzoate; mint flavor]

Generic: 1 mg/5 mL (5 mL [DSC], 10 mL [DSC], 118 mL [DSC]); 1 mg/7.5 mL (120 mL)

Suspension, Oral, as hydrochloride:

Generic: 1 mg/7.5 mL (120 mL)

Tablet, Oral, as hydrochloride:

Anti-Diarrheal: 2 mg [scored]

Anti-Diarrheal: 2 mg [scored; contains brilliant blue fcf (fd&c blue #1), corn starch, fd&c yellow #10 (quinoline yellow)]

Anti-Diarrheal: 2 mg [DSC] [contains brilliant blue fcf (fd&c blue #1), fd&c yellow #10 (quinoline yellow)]

Anti-Diarrheal: 2 mg [scored; contains brilliant blue fcf (fd&c blue #1), fd&c yellow #10 (quinoline yellow)]

Anti-Diarrheal: 2 mg [contains fd&c blue #1 aluminum lake, fd&c yellow #10 (quinoline yellow)]

Diamode: 2 mg [scored]

Imodium A-D: 2 mg [scored; contains fd&c blue #1 aluminum lake, fd&c yellow #10 aluminum lake]

Loperamide A-D: 2 mg [DSC]

Anatomic Therapeutic Chemical (ATC) Classification

• A07DA03

Generic Available (US)

Yes

Pricing: US

Capsules (Imodium A-D Oral)

2 mg (per each): $0.46

Capsules (Loperamide HCl Oral)

2 mg (per each): $0.87 - $1.37

Liquid (Imodium A-D Oral)

1 mg/7.5 mL (per mL): $0.04

Liquid (Loperamide HCl Oral)

1 mg/7.5 mL (per mL): $0.04

Tablets (Imodium A-D Oral)

2 mg (per each): $0.42

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Acts directly on circular and longitudinal intestinal muscles, through the opioid receptor, to inhibit peristalsis and prolong transit time; reduces fecal volume, increases viscosity, and diminishes fluid and electrolyte loss; demonstrates antisecretory activity. Loperamide increases tone on the anal sphincter

Pharmacodynamics/Kinetics

Absorption: Poor

Distribution: Poor penetration into brain

Metabolism: Hepatic via oxidative N-demethylation; CYP2C8 and CYP3A4 (major) and CYP2B6 and CYP2D6 (minor) role in N-demethylation.

Half-life elimination: 9.1 to 14.4 hours

Time to peak, plasma: Liquid: 2.5 hours; Capsule: ~5 hours

Excretion: Feces

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

Key adverse event(s) related to dental treatment: Rare occurrences of erythema multiforme, Stevens-Johnson syndrome, and xerostomia (normal salivary flow resumes upon discontinuance) have been reported.

Effects on Bleeding

No information available to require special precautions

Index Terms

Loperamide HCl; Loperamide Hydrochloride

FDA Approval Date

December 28, 1976

References

Abigerges D, Armand JP, Chabot GG, et al, “Irinotecan (CPT-11) High-Dose Escalation Using Intensive High-Dose Loperamide to Control Diarrhea,” J Natl Cancer Inst, 1994, 86(6):446-9.[PubMed 8120919]

Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317-319.[PubMed 11487763]

Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncol. 2014;15(10):e447-e460. doi: 10.1016/S1470-2045(14)70006-3.[PubMed 25186048]

Benson AB 3rd, Ajani JA, Catalano RB, et al, "Recommended Guidelines for the Treatment of Cancer Treatment-Induced Diarrhea," J Clin Oncol, 2004, 22(14):2918-26.[PubMed 15254061]

Buts JP, Petit BF, and de Meyer R, "Letter: Loperamide in Treatment of Persistent Diarrhoea in Children," Br Med J, 1975, 3(5986):766-7.[PubMed 1174894]

Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. MMWR Morb Mortal Wkly Rep. 1982;31(22):290-291. http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm[PubMed 6810084]

Centers for Disease Control and Prevention (CDC), "Managing Acute Gastroenteritis Among Children: Oral Rehydration, Maintenance, and Nutritional Therapy," MMWR Recomm Rep, 2003, 52(RR-16):1-16.[PubMed 14627948]

Centers for Disease Control and Prevention. The pre-travel consultation: travelers' diarrhea. The Yellow Book: CDC health information for international travel, 2018. https://wwwnc.cdc.gov/travel/yellowbook/2018/the-pre-travel-consultation/travelers-diarrhea. Updated June 13, 2017. Accessed September 6, 2017.

Children's Oncology Group. Supportive care guidelines. https://childrensoncologygroup.org/downloads/Supportive%20Care%20Guidelines_ARCHIVED_10-7-09_Diarrhea_AUGUST2018.pdf. Updated 2009.

Einarson A, Mastroiacovo P, Arnon J, et al, "Prospective, Controlled, Multicentre Study of Loperamide in Pregnancy," Can J Gastroenterol, 2000, 14(3):185-7.[PubMed 10758415]

Ericsson CD, "Nonantimicrobial Agents in the Prevention and Treatment of Traveler's Diarrhea," Clin Infect Dis, 2005, 41(Suppl 8):557-63.

Ericsson CD and Johnson PC, “Safety and Efficacy of Loperamide,” Am J Med, 1990, 88(6A):10S-14S.[PubMed 2192552]

Hamdi I and Dodge JA, "Toddler Diarrhoea: Observations on the Effects of Aspirin and Loperamide," J Pediatr Gastroenterol Nutr, 1985, 4(3):362-5.[PubMed 3926980]

Hill DR, Ericsson CD, Pearson RD, et al. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clin Infect Dis. 2006;43(12):1499-1539.[PubMed 17109284]

Imodium [product monograph]. Markham, Ontario, Canada: McNeil Consumer Healthcare; December 2016.

Imodium A-D (loperamide) caplets [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Division; received March 2019.

Imodium A-D (loperamide) oral solution [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Division; received August 2019.

Imodium A-D (loperamide) tablets [prescribing information]. Fort Washington, PA: McNeil Consumer Healthcare Division; received April 2017.

"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. Pediatrics. 1997;99(2):268-278.[PubMed 9024461]

Källén B, Nilsson E, and Otterblad Olausson P, "Maternal Use of Loperamide in Early Pregnancy and Delivery Outcome," Acta Paediatr, 2008, 97(5):541-5.[PubMed 18394096]

Kornblau S, Benson AB, Catalano R, et al, “Management of Cancer Treatment-Related Diarrhea. Issues and Therapeutic Strategies,” J Pain Symptom Manage, 2000, 19(2):118-29.[PubMed 10699539]

Li ST, Grossman DC, and Cummings P, "Loperamide Therapy for Acute Diarrhea in Children: Systematic Review and Meta-analysis," PLoS Med, 2007, 4(3):e98.[PubMed 17388664]

Loperamide hydrochloride [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; October 2016.

Morturano R. Management of chemotherapy-induced diarrhea. OncoLink. https://www.oncolink.org/healthcare-professionals/o-pro-portal/articles-about-cancer-treatment-and-medications/management-of-chemotherapy-induced-diarrhea. Updated October 2012.

Nerlynx (neratinib) [prescribing information]. Los Angeles, CA: Puma Biotechnology, Inc; June 2018.

Nikodem VC and Hofmeyr GJ, "Secretion of the Antidiarrhoeal Agent Loperamide Oxide in Breast Milk," Eur J Clin Pharmacol, 1992, 42(6):695-6.[PubMed 1623917]

Park JW, Liu MC, Yee D, et al; I-SPY 2 Investigators. Adaptive randomization of Neratinib in early breast cancer.N Engl J Med. 2016;375(1):11-22. doi: 10.1056/NEJMoa1513750.[PubMed 27406346]

Riddle MS, DuPont HL, Connor BA. ACG Clinical Guideline: Diagnosis, treatment, and prevention of acute diarrheal infections in adults. Am J Gastroenterol. 2016;111(5):602-622.[PubMed 27068718]

Rothenberg ML, Eckardt JR, Kuhn JG, et al, "Phase II Trial of Irinotecan in Patients With Progressive or Rapidly Recurrent Colorectal Cancer," J Clin Oncol, 1996, 14(4):1128-35.[PubMed 8648367]

Sandhu BK, Tripp JH, Milla PJ, et al, "Loperamide in Severe Protracted Diarrhoea," Arch Dis Child, 1983, 58(1):39-43.[PubMed 6830273]

Shane AL, Mody RK, Crump JA, et al. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. Clin Infect Dis. 2017;65(12):e45-e80.[PubMed 29053792]

Sharma R, Tobin P, and Clarke SJ, “Management of Chemotherapy-Induced Nausea, Vomiting, Oral Mucositis, and Diarrhoea,” Lancet Oncol, 2005, 6(2):93-102.[PubMed 15683818]

Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. Pediatr Crit Care Med. 2009;10(2):256-259.[PubMed 19188870]

Siegel RL, Ferris FD, Becker G, et al. NCCN Clinical Practice Guideline in Oncology: Palliative care. Epub March 2017.

Swain SM, Schneeweiss A, Gianni L, et al. Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab. Ann Oncol. 2017;28(4):761-768. doi: 10.1093/annonc/mdw695.[PubMed 28057664]

Vassal G, Couanet D, Stockdale E, et al, "Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group," J Clin Oncol, 2007, 25(4):356-61.[PubMed 17264330]

Wald A, "Constipation, Diarrhea, and Symptomatic Hemorrhoids During Pregnancy," Gastroenterol Clin North Am, 2003, 32(1):309-22.[PubMed 12635420]

Brand Names: International

Abydium (LK); Albutil (BD); Arret (IE); Beamodium (MY); Betaperamide (ZA); Binaldan (CH); Blotasime (EG); Cicamin (PY); Colidium (ID); Colifilm (AR); Coliper (CL); Colodium (HK); Contem (PY); D-Stop-ratiopharm (LU); Degortkap (CR, DO, GT, HN, NI, PA, SV); Diadium (ID); Diamide (NZ); Diaperol (MX); Diarlop (IN); Diarodil (TH); Diatabs (PH); Diatrol (SG); Dissenten (IT); Donafan (PE); Donamed F (PE); Dyspagon (LU); Elcoman (AR); Fortasec (ES); Gastro-Stop (AU); Gastron (ZA); Good Sense Anti-Diarrheal (HK); Harmonise (AU); Hocular (TW); Hrindeks (UA); Imodium (AE, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BS, CH, CI, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, KE, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PR, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SK, SL, SN, SR, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, VE, VN, YE, ZA, ZM, ZW); Imodonil (HK); Imonox (TH); Imosec (BR); Imosen (TW); Imossel (FR); Imotil (LK); Inamid (ID); Lenide-T (ZA); Lockit (ZW); Lodia (ID); Lomedium (VN); Lomid (BD); Lomotil (MX); Loniper (PH); Lopamid (BD); Lopamide (BH, ET, IN); Lopedin (TW); Lopedium (HU, LU, UA); Lopemid (IT); Loper (HK); Loperamid-ratiopharm (LU); Loperamide-Eurogenerics (LU); Loperamide-Generics (LU); Loperamil (HK, SG); Loperhoe (DE); Loperium (BB, BM, BS, BZ, GY, JM, MT, NL, SR, TT); Lopermid (TR); Lopermide (HK); Lopicare (IL); Lopide (BD); Lopmin (KR); Loprid (RO); Lopron (PH); Loramide (LK, SG); Lordiar (HR); Lorid (BD); Luobaomai (CN); Motilex (ID); NT-Diorea (HK); Pangetan NF (CO); Paradoxone (ET); Perasian (TH); Permid (PH); Ramide (ET); Regulane (AR); Rexamide (IL); Reximide (MY); Rhomuz (ID); Safe (TW); Salvacolina (ES); Sanpo (TW); Seldiar (HR); Stoperan (UA); Stopit (IL); Stoprrhea (EG); Suprasec (AR); Tarmin (CR, DO, GT, HN, NI, PA, SV); Toban (PE); Toban F (PE); Undiarrhea (TW); Vacontil (AE, BF, BH, BJ, CI, CY, ET, GH, GM, GN, IQ, JO, KE, KW, LB, LR, MA, ML, MR, MU, MW, MY, NE, NG, OM, QA, SC, SD, SL, SN, TN, TZ, UG, VN, ZM, ZW); Vancotil (SG); Velaral (EC)

Last Updated 2/21/20